CANT1: A Promising Protein for Drug Targeting and Biomarker Development

Target Name: CANT1

NCBI ID: G124583

CANT1

CANT1: A Promising Protein for Drug Targeting and Biomarker Development

CANT1 (apyrase 1 homolog) is a protein that is expressed in a variety of organisms, including bacteria, archaea, and eukaryotes. It is a member of the APYLASE family, which is characterized by the presence of a specific catalytic domain in the protein sequence.

One of the unique features of CANT1 is its ability to catalyze the oxidation of a wide range of substrates, including fatty acids, amino acids, and nucleic acids. This ability makes it a potentially interesting drug target, as drugs that can inhibit the activity of CANT1 could be useful in treating a variety of diseases.

In addition to its catalytic activity, CANT1 has also been shown to play a role in the regulation of cellular processes. For example, studies have shown that CANT1 is involved in the regulation of the expression of genes involved in cell growth, differentiation, and stress responses.

CANT1 is also expressed in the liver, which is a key organ that is involved in the detoxification of a wide range of substances. As a result, CANT1 has also been shown to be involved in the regulation of cellular processes that are critical for liver function.

In addition to its potential drug-targeting properties, CANT1 is also of interest as a biomarker. The ability of CANT1 to catalyze the oxidation of a wide range of substrates makes it a potentially useful marker for the diagnosis and monitoring of a variety of diseases. For example, CANT1 has been used as a biomarker for the diagnosis of cancer, as it has been shown to be highly expressed in cancer cells compared to normal cells.

Another potential application of CANT1 as a drug target is its role in the regulation of cellular processes that are involved in the development and progression of diseases. For example, studies have shown that CANT1 is involved in the regulation of the migration and invasion of cancer cells. This makes it a potentially interesting target for anti-cancer drugs that can inhibit its activity.

In addition to its potential drug and biomarker applications, CANT1 is also of interest as a potential therapeutic agent for a variety of other diseases. For example, its ability to catalyze the oxidation of a wide range of substrates makes it a potentially interesting target for the treatment of diseases that are characterized by the buildup of fatty acids or other types of waste products in the body.

Overall, the protein CANT1 is a promising candidate for a variety of different applications, including drug targeting, biomarker development, and therapeutic intervention. Further research is needed to fully understand its role in cellular processes and its potential as a therapeutic agent.

Protein Name: Calcium Activated Nucleotidase 1

Functions: Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP (PubMed:12234496, PubMed:15248776, PubMed:15006348, PubMed:16835225). Involved in proteoglycan synthesis (PubMed:22539336)

The "CANT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CANT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets